Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15(1):363.

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.

Lee-Saxton YJ, Egan CE, Bratton BA, Thiesmeyer JW, Greenberg JA, Marshall TE, et al. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence. J Clin Endocrinol Metab. 2024.

Xu X, Feng J, Wang X, Zeng X, Luo Y, He X, et al. Mitochondrial GRIM19 Loss Induces Liver Fibrosis through NLRP3/IL33 Activation via Reactive Oxygen Species/NF-кB Signaling. J Clin Transl Hepatol. 2024;12(6):539-550.

Nooruzzaman M, Johnson KE, Rani R, Finkelsztein EJ, Caserta LC, Kodiyanplakkal RP, et al. Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. medRxiv. 2024.

Li Y, Deng K, Kaner J, Geyer JT, Ouseph M, Fang F, et al. Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements. Pathobiology. 2024;91(1):76-88.

Lo Y, Lester SC, Ellis IO, Lanjewar S, Laurini J, Patel A, et al. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Arch Pathol Lab Med. 2024;148(10):1119-1125.

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.